The Impact of the Bay-Dole Act on Pharmaceutical Innovation

This chapter explores the Biden administration's changing position on IP protections for COVID-19 vaccines, examining the historical relationship between the government and pharmaceutical companies. It critiques the impact of the Bay-Dole Act of 1980, suggesting that it has fostered a corporate focus on profit rather than patient care in drug development.